Latest Biotechnology, Pharmaceutical and Healthcare News from Proactive Investors

13:21 EDT 21st October 2018 | BioPortfolio

Here are the most relevant search results for "Proactive Investors" found in our extensive news archives from over 250 global news sources.

More Information about Proactive Investors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Proactive Investors for you to read. Along with our medical data and news we also list Proactive Investors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Proactive Investors Companies for you to search.

Showing News Articles 1–25 of 1,800+ from Proactive Investors

Friday 19th October 2018

Why graphene hasn’t taken over the world … yet

Liberum analyst Yuan Low says it is still early on in graphene’s development, but he has “no doubt” over its “wonder material” status and its potential further down the line

Nemaura Medical targeting year-end for UK launch of its glucose monitor

Faz Chowdhury, chief executive of Nemaura Medical Inc (NASDAQ:NMRD), spoke to Proactive London's Andrew Scott to update on their European and FDA trials as work continues towards the launch in the UK of their non-invasive glucose monitor by the end of the year. ''We believe it'll be the world's first non-invasive glucose monitoring system''. ''It's a continuous monitor, you place it on the a...

SELLAS Life Sciences Group updates on final results of Phase 2b study on breast cancer patients

Final analysis identifies patients with triple negative breast cancer (TNBC) as the key target patient population for the drug.

Anavex Life Sciences shares rise after FDA gives green light on Phase 2 trial

Its drug Anavex2-73 is being developed to treat Rett Syndrome, a rare neurological disorder that occurs mainly in girls and can lead to severe impairments

hVIVO builds on position of strength in challenge trials

Respiratory syncytial virus causes the common cold, for which there is no effective cure.

Essentra's third quarter statement a bit of a curate's egg

For the first nine months of 2018, the businesses Essentra is looking to exit made an operating loss of around £1mln. The closures would result in an exceptional charge in the second half of 2018 of about £12mln, of which roughly £4mln would be a cash charge

Dechra Pharma moves into South America with £38mln acquisition of Venco

The acquisition provides Dechra with a “strategically important presence” in Brazil, the fourth largest livestock market in the world

ChemioCare gets DEA clearance to introduce dronabinol patch for cancer patients

Successful registration with the DEA by its partner Transdermal cracks the door to begin formula development of a dronabinol transdermal patch

Arix Bioscience pours another £5.4mln into LogicBio as investee company lists on Nasdaq

As a result of the IPO, the value of Arix’s stake in LogicBio has soared to almost £23mln, including the extra investment announced today

Futura Medical raises funds to finance its erectile dysfunction gel through Phase 3 studies

Three directors have subscribed for shares. Two independent directors have consulted with Futura's nomad and deemed that the terms of the participating directors' participation in the subscription is "fair and reasonable"

Why Viking Therapeutics isn’t waiting for a white knight

The small-cap biotech appears to have addressed any need for a deep-pocketed partner while it develops not one but two potential blockbuster therapies

Thursday 18th October 2018

Lexaria Bioscience granted two new US patents

The company announced Thursday it has been granted two new US patents related to cannabinoid infused beverage compositions

Aethlon Medical CEO says 'time is right' to move Aethlon Hemopurifier to human studies

Aethlon Medical Inc (NASDAQ:AEMD) CEO Jim Joyce spoke with Proactive Investor's Christine Corrado at the BIO Investor Forum in San Francisco. The San Diego based company is focused on addressing unmet needs in global health and biodefense with the Aethlon Hemopurifier, a therapeutic device designed for the rapid depletion of circulating viruses and cancer promoting exosomes.

Berlin Cures gears up to begin phase 2 clinical trials end of 2018

Berlin Cures Holding AG President Joannes Müller and COO Peter Göttel sit down with Proactive Investors' Christine Corrado at the BIO Investor Summit in San Francisco.  Berlin Cures Holding AG is a life science company, located in Zug, Switzerland with an R&D-branch in Berlin, Germany.     

Sernova enrolling patients in Phase 1/2 clinical trial for its Cell Pouch device

Sernova Corp (TSX-V: SVA, OTCQB: SEOVF) CEO Philip Toleikis sat down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco. Sernova focuses on developing medical devices and products for patients suffering from chronic metabolic, neurological, and haematological diseases. The company's flagship product is its Cell Pouch system, a medical device which forms a ...

Hillstream BioPharma looks forward to pre-IND discussion with FDA in Q4

Hillstream BioPharma CEO Randy Milby sits down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco. Hillsteam BioPharma is developing targeted cancer therapeutics designed to be safer and more efficacious than currently available chemo-therapies.

EpicentRx leaders look to turn cancer into a chronic disease from a deadly disease

Bryan Oronsky and James Brown from EpicentRx sit down with Christine Corrado at the BIO Investor Forum in San Francisco. EpicentRx is a biotechnology company developing a next-generation immunotherapy platform of viruses that infect and kill cancer cells for the treatment of several tumor types.

Endocyte Inc shares soar after Novartis pays $2.1 billion for company, shares finish over 50% higher

Novartis will use its resources to develop an Endocyte treatment for prostate cancer

WideCells reshuffles boardroom as part of its growth plans

Chairman Peter Presland will take on a more active role to free up more time for CEO João Andrade to focus on sales and business development

ChemioCare 'exceeding expectations' with pace of developing its technology

ChemioCare USA Inc CEO Pedro Lichtinger sits down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco. Lichtinger says the New York based company, which is aiming to transform patient outcomes in cancer supportive care through its platform of transdermal patches using proprietary technology, says the company has completed its first proof of concept in animals...

Sativa Investments announces £3.75mln equity raise and plans to build UK cannabis greenhouse

Sativa Investments has taken a big step towards becoming the UK's first seed to consumer medicinal cannabis business

Matinas BioPharma shares pop on patent approval for MAT9001

The patent covers methods of use for its omega-3 fatty acid therapy, which is in development for the treatment of heart conditions and high cholesterol

Epygen Group shifts from biotech in oil & gas to bio-pharmaceuticals

Epygen Group President Debayan Ghosh sits down with Christine Corrado at the BIO Investor Forum in San Francisco. Epygen is a biotechnology organization, headquartered in Dubai, UAE, with offices, labs and manufacturing facilities in Dubai, India, and the US. Epygen conducts research and manufacturing of a wide range of enzymes proteins for the therapeutic as well as industrial enzyme space.

Zynerba Pharmaceuticals anticipates data in late 2019 for its phase 3 cannabinoid drug

Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco. Zynerba is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs.

Breakthrough to open up potential new revenue opportunities for Reneuron Plc

Michael Hunt, CFO at Reneuron Plc (LON:RENE), spoke to Proactive ahead of new data being presented at the 26th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) relating to its CTX stem cell platform. The platform is currently being taken through the clinic as a possible treatment for stroke patients, with long-term data suggesting it can improvement motor function and r...

Quick Search


News Quicklinks